Abstract
The therapeutic index of antineoplastic therapies has traditionally been driven by the concepts of maximally tolerated dose and treatment response. When the tumor is viewed as homogeneous with respect to response, and response is defined by tumor regression, there are many effective antineoplastic regimens. However, the persistent problem of cancer recurrence in the face of apparently successful therapy, and the recognition that tumors are at least as heterogeneous as normal tissue, necessitates a reevaluation of the concept of therapeutic index from the standpoint of the most therapy resistant cells within the tumor vs. the maximal disruption that critical tissues can withstand. The cancer stem cell paradigm helps explain some of the heterogeneity within tumors and posits that therapy resistance originates with the strategies by which normal tissue stem cells protect themselves from toxic insults. The recognition that at any given time, self-renewing (tumorigenic) tumor cells are protected by mechanisms, such as multiple drug resistance (MDR) transporters, detoxifying enzymes, a resting state, and niche effects, ensures that a proportion of tumor cells will have toxicity profiles similar to normal tissue stem cells. The problem of therapeutic index is compounded by the fact that clonogenic cancer cells have merely to survive and reactivate to perpetuate the neoplasm, whereas vital organ functions cannot be compromised for long without lethal consequences. In this chapter, we review the evolving concepts of therapeutic index, maximal tolerated dose, and tumor heterogeneity in the context of the cancer stem cell paradigm. Primary clinical isolates are used to provide examples of heterogeneity within the tumorigenic compartment, within cells that resist therapy, and within cells protected by MDR transporters.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thomas E, Storb R, Clift RA, et al Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292(16):832–43.
Santos GW, Owens AH, Jr. Allogeneic marrow transplants in cyclophosphamide treated mice. Transplant Proc 1969;1(1):44–6.
Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Haematopoietic chimera in man after allogenic (homologous) bone-marrow transplantation. (control of the secondary syndrome. Specific tolerance due to the chimerism). Br Med J 1963;2(5373):1633–5.
Quastler H. Studies on roentgen death in mice. I. Survival time and dosage. Am J Roentgenol 1945;45:449–56.
Mehta J, Powles R, Sirohi B, et al Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes? Bone Marrow Transplant 2003;32(2):157–64.
Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006;24(12):2603–10.
Blazar BR, Orr HT, Arthur DC, Kersey JH, Filipovich AH. Restriction fragment length polymorphisms as markers of engraftment in allogeneic marrow transplantation. Blood 1985;66(6):1436–44.
Frei E, 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res 1998;4(9):2027–37.
Mertens AC. Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer 2007;48(7):723–6.
Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98(16):1108–17.
Ceelen WP, Morris S, Paraskeva P, Pattyn P. Surgical trauma, minimal residual disease and locoregional cancer recurrence. Cancer Treat Res 2007;134:51–69.
Vidal-Vanaclocha F, Mendoza L, Telleria N, et al Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006;25(3):417–34.
Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999;341(7):491–7.
Alonso L, Fuchs E. Stem cells of the skin epithelium. Proc Natl Acad Sci USA 2003;100(Suppl 1):11830–5.
Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7(11):834–46.
Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 2007;67(19):8985–8.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983–8.
Li C, Heidt DG, Dalerba P, et al Identification of pancreatic cancer stem cells. Cancer Res 2007;67(3):1030–7.
O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106–10.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006;103(30):11154–9.
Singh SK, Clarke ID, Terasaki M, et al Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63(18):5821–8.
Dirks PB. Cancer: stem cells and brain tumours. Nature 2006;444(7120):687–8.
Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67(14):6796–805.
Donnenberg VS, Luketich JD, Landreneau RJ, DeLoia JA, Basse P, Donnenberg AD. Tumorigenic epithelial stem cells and their normal counterparts. Ernst Schering Found Symp Proc 2006;5:245–63.
Giangreco A, Shen H, Reynolds SD, Stripp BR. Molecular phenotype of airway side population cells. Am J Physiol Lung Cell Mol Physiol 2004;286(4):L624–30.
Cereghini S, Yaniv M, Cortese R. Hepatocyte dedifferentiation and extinction is accompanied by a block in the synthesis of mRNA coding for the transcription factor HNF1/LFB1. Embo J 1990;9(7):2257–63.
Rulifson IC, Karnik SK, Heiser PW, et al Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 2007;104(15):6247–52.
Huntly BJ, Gilliland DG. Cancer biology: summing up cancer stem cells. Nature 2005;435(7046):1169–70.
Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48(8):1996–2004.
Bertoncello I, Williams B. Hematopoietic stem cell characterization by Hoechst 33342 and rhodamine 123 staining. Methods Mol Biol 2004;263:181–200.
Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. Faseb J 2006;20(8):1045–54.
Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66(1):85–94.
Zhou S, Zong Y, Lu T, Sorrentino BP. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques 2003;35(6):1248–52.
Singer TS, Sulkes A, Biran S. Pleural effusion in breast cancer: influence upon clinical course and survival. Chemioterapia 1986;5(1):66–9.
Lum BL, Fisher GA, Brophy NA, et al Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993;72(11 Suppl):3502–14.
O’Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 2004;50(5):826–35.
Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med 2007;27(3):627–52, viii.
Elder E, Whiteside, TL. Processing of Tumors for Vaccine and/or Tumor Infiltrating Lymphocytes. In: Rose N, Conway de, Macario, E, Fahey, JL, Friedman, H, Prnn, GM, eds. Manual of Clinical Laboratory Immunology, 4th Edition: American Society for Microbiology; 1992:817–9.
Donnenberg VS, Landreneau RJ, Donnenberg AD. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release 2007;122(3):385–91.
Acknowledgments
This work was supported by grants BC032981 and BC044784 from the Department of Defense, the Hillman Foundation and the Glimmer of Hope Foundation. Vera Donnenberg is a CDMRP Era of Hope Scholar. The authors thank Ms. Darlene Monlish, Ms. Melanie Pfeifer, Mr. E. Michael Meyer, and Mr. Ludovic Zimmerlin for their expert technical assistance, and Drs. Rodney Landreneau and Shannon Puhalla for providing samples and clinical expertise. We also thank Mr. Peter Nobes and Mr. David Roberts of Applied Cytometry for the opportunity to collaborate on the development of software specifically designed for multiparameter rare event analysis on large datafiles.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Donnenberg, V.S., Donnenberg, A.D. (2009). Therapeutic Index and the Cancer Stem Cell Paradigm. In: Teicher, B., Bagley, R. (eds) Stem Cells and Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-60327-933-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-60327-933-8_24
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-932-1
Online ISBN: 978-1-60327-933-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)